logo
Plus   Neg
Share
Email

Genentech's Late-stage Study On Pemphigus Vulgaris Meets Primary Endpoint

Genentech, a member of the Roche Group (RHHBY), reported that late-stage PEMPHIX study showed its Rituxan or rituximab superior to Mycophenolate Mofetil in patients with pemphigus vulgaris.

The study met the primary endpoint at week 52, with 40.3% of patients treated with Rituxan achieving sustained complete remission (CR) without the use of steroids for 16 consecutive weeks or more, compared to 9.5% in the mycophenolate mofetil arm. All secondary endpoints were statistically significant in favor of Rituxan.

"The PEMPHIX study showed that 40% of people in the study could achieve complete remission from painful blistering without the need for corticosteroids for 16 weeks or more and that Rituxan may be a superior treatment option to mycophenolate mofetil," said Levi Garraway, chief medical officer and head of Global Product Development.

Pemphigus vulgaris is a rare, serious and potentially life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes. Mycophenolate Mofetilis an unapproved, commonly used treatment for Pemphigus vulgaris that is recommended in published treatment guidelines.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
J. M. Smucker Co. is recalling certain Natural Balance canned cat food, citing health concerns likely associated with increased levels of choline chloride, an animal growth promotant, the U.S. Food and Drug Administration said in a statement. The recall was initiated after receiving reports of adverse reactions. Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19.
Follow RTT